Corvus Pharmaceuticals Net Tangible Assets

Corvus Pharmaceuticals (CRVS) currently reports a net tangible assets of $230M as of June 2026. That compares with $80M in the prior-year period — up 180.9% year over year. Use the charts on this page to explore Corvus Pharmaceuticals's net tangible assets history and peer comparisons.

Corvus Pharmaceuticals's net tangible assets increased from $80M to $230M — a 180.9% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Corvus Pharmaceuticals reported $230M in net tangible assets as of June 2026. That compares with $80M in the prior-year period — up 180.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net tangible assets of $230M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Corvus Pharmaceuticals, and consider following CRVS for alerts when major investors trade the stock.

Corvus Pharmaceuticals is classified in the Healthcare sector. On net tangible assets, it currently shows $230M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CRVS with unrelated industries.